9. Dezember 2020 – In a recent decision, the Federal Supreme Court held that when conducting a therapeutic cross comparison (TCC), therapies that are more effective and/or better tolerated than the initial preparation may be disregarded. Instead, the comparison may be limited to equally effective, less expensive medicines. The appeal was dismissed.

For the full decision, see here.